2-iso-Butyl-5-ethyl-1,3,4-thiadiazol | 41398-06-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-iso-Butyl-5-ethyl-1,3,4-thiadiazol
• 英文别名: 2-ethyl-5-isobutyl-[1,3,4]thiadiazole；2-Ethyl-5-(2-methylpropyl)-1,3,4-thiadiazole
• CAS: 41398-06-5
• 化学式: C₈H₁₄N₂S
• 分子量: 170.279
• InChiKey: TUBFGCNOFHUGLB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-methyl-butyric acid N'-propionyl-hydrazide 在 tetraphosphorus decasulfide 作用下， 生成 2-iso-Butyl-5-ethyl-1,3,4-thiadiazol
  参考文献：
  名称：

  Lund,H., Acta Chemica Scandinavica (1947), 1973, vol. 27, p. 391 - 395

  摘要：

  DOI：

文献信息

• Substituted Aminobutyric Derivatives as Neprilysin Inhibitors
  申请人：Coppola Gary Mark

  公开号：US20120252830A1

  公开（公告）日：2012-10-04

  The present invention provides a compound of formula I′; or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , X and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了公式I'的化合物；或其药学上可接受的盐，其中R1、R2、R3、X和n在此定义。本发明还涉及制造本发明化合物的方法及其治疗用途。本发明还提供了一种药理活性剂的组合和制药组合物。
• Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US11530210B2

  公开（公告）日：2022-12-20

  Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.

  取代的吡唑并吡啶作为 GluN2B 受体配体。此类化合物可用于调节 GluN2B 受体，以及用于治疗由 GluN2B 受体活性介导的疾病状态、紊乱和病症的药物组合物和方法。
• SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20210017169A1

  公开（公告）日：2021-01-21

  Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.